Epperla, Narendranath
Welkie, Rina Li
Torka, Pallawi
Shouse, Geoffrey
Karmali, Reem
Shea, Lauren
Anampa-Guzmán, Andrea
Oh, Timothy S.
Reaves, Heather
Tavakkoli, Montreh
Lindsey, Kathryn
Greenwell, Irl Brian
Hansinger, Emily
Thomas, Colin
Chowdhury, Sayan Mullick
Annunzio, Kaitlin
Christian, Beth
Barta, Stefan K.
Geethakumari, Praveen Ramakrishnan
Bartlett, Nancy L.
Herrera, Alex F.
Grover, Natalie S.
Olszewski, Adam J.
Article History
Received: 26 February 2023
Accepted: 3 May 2023
First Online: 8 May 2023
Declarations
:
: The study was approved by the institutional review boards at all the participating sites and performed in compliance with the Declaration of Helsinki.
: Not applicable.
: NE: Research funding: Beigene, Speakers Bureau for Incyte and Beigene, Honoraria/consulting/ad boards for Merck, ADC Therapeutics, Lilly, Novartis. PT: Honoraria/consulting/ad boards for TG Therapeutics, ADC Therapeutics, Genentech, GenMab and Lilly USA. GS: Honoraria from Kite Pharmaceuticals and BeiGene. RK: Advisory Board: BMS, Gilead Sciences./Kite Pharma, Janssen, Karyopharm, Pharmacyclics, Morphosys, Epizyme, Genentech/Roche, EUSA, Calithera; Grants/Research Support: BMS, Takeda, BeiGene, Gilead Sciences/Kite, Calithera. Speakers Bureau: AstraZeneca, BeiGene, Morphosys. IBG: Ad boards for Kite, Stemline. BC: Research funding: Genentech, Acerta, Triphase, MorphoSys, SeaGen, Millenium, Bristol-Myers Squibb, F Hoffman-La Roche; Advisory Board: Genentech, ADC Therapeutics. SKB: Honoraria: Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, Seagen. PRG: Consultancy services to Kite Pharma, Bristol Myers Squibb and Rafael Pharma and served on the advisory boards of Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences and Ono Pharma. NLB: Research funding: ADC Therapeutics, Autolus, BMS, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Merck, Millennium, Pharmacyclics, Affirmed Therapeutics, Dynavax, Gilead, MedImmune, Novartis; Consulting/Ad board: Kite Pharma, Pfizer, ADC Therapeutics, Roche/Genentech, Seattle Genetics, BTG, Acerta. AFH: Consultancy: BMS, Merck, Gilead, Adaptive Biotech, Seattle Genetics, Karyopharm; Research funding: Merck, Genentech, Gilead, Seattle Genetics, Immune Design, AstraZeneca, Pharmacyclics, ADCT Therapeutics. NSG: Research funding: Genentech, Tessa Therapeutics, Honoraria/consulting/ ad boards for ADC Therapeutics, Genentech, Kite, Novartis, Tessa Therapeutics and Seattle Genetics. AO: Genmab; Precision Bio; Adaptive Biotechnologies; Celldex; Acrotech Biopharma; Schrodinger; TG Therapeutics; Genentech. RLW, LS, A.A-G, TSO, HR, MT, KL, EH, CT, SMC, and KA have not relevant COI.